Aptose Biosciences Inc. (NASDAQ:APTO) was up 2.7% during mid-day trading on Tuesday . The stock traded as high as $2.32 and last traded at $2.26, with a volume of 54,874 shares. The stock had previously closed at $2.20.

Several equities research analysts recently issued reports on APTO shares. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Aptose Biosciences in a research report on Thursday, June 9th. Canaccord Genuity reissued a “buy” rating and issued a $7.00 target price on shares of Aptose Biosciences in a research report on Thursday, June 9th. Roth Capital raised shares of Aptose Biosciences from a “neutral” rating to a “buy” rating and raised their target price for the stock from $4.00 to $8.00 in a research report on Monday, June 13th. Royal Bank Of Canada reissued an “outperform” rating and issued a $23.00 target price on shares of Aptose Biosciences in a research report on Monday, June 13th. Finally, Zacks Investment Research cut shares of Aptose Biosciences from a “hold” rating to a “sell” rating in a research report on Friday, August 12th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $12.30.

The firm’s market cap is $27.06 million. The firm’s 50-day moving average price is $2.46 and its 200 day moving average price is $2.62.

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.